04-290
Anti-EGFR (CT) Antibody, clone 13G8
clone 13G8, from mouse
Synonym(s):
ERBB, mENA, ERBB1
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
mouse
Quality Level
antibody form
purified antibody
antibody product type
primary antibodies
clone
13G8, monoclonal
species reactivity
mouse, human
manufacturer/tradename
Chemicon®
Upstate®
technique(s)
ELISA: suitable
immunocytochemistry: suitable
western blot: suitable
isotype
IgG1
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Gene Information
human ... EGFR(1956)
mouse ... Egfr(13649)
Specificity
Recognizes C-terminus domain of EGF receptor (aa1165-1186)
Immunogen
KLH-conjugated synthetic peptide encompassing the surrounding amino acids of the C terminus in human EGFR
Application
Anti-EGFR (C-terminus) Antibody, clone 13G8 detects level of EGFR (C-terminus) & has been published & validated for use in ELISA, IC & WB.
Research Category
Signaling
Signaling
Research Sub Category
Growth Factors & Receptors
Growth Factors & Receptors
Quality
Routinely evaluated by immunoblot.
Target description
180 kDa
Linkage
Replaces: 04-337; 04-338
Physical form
100 µg of purified mouse monoclonal IgG lyophilized in PBS containing 0.09% sodium azide, PEG, and sucrose
Format: Purified
Subsequent thiophilic adsorption and size exclusion chromatography
Storage and Stability
2 years at -20°C from date of shipment
Analysis Note
Control
Includes EGF treated Hep2G lysate as a positive control
Includes EGF treated Hep2G lysate as a positive control
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
recommended
Product No.
Description
Pricing
Storage Class Code
10 - Combustible liquids
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Francesca Walker et al.
Experimental cell research, 313(3), 511-526 (2006-12-13)
The site of action of growth factors on mammalian cell cycle has been assigned to the boundary between the G1 and S phases. We show here that Epidermal Growth Factor (EGF) is also required for mitosis. BaF/3 cells expressing the
Katsuyuki Hotta et al.
Oncology reports, 17(2), 313-317 (2007-01-05)
Despite its tremendous antitumor effect in a subset of patients with non-small cell lung cancer (NSCLC), the exact mechanism of gefitinib-induced cell death has not been fully determined. In this study, forms of cell death in various NSCLC cell lines
Xiaozhu Zhang et al.
Journal of medical genetics, 44(3), 166-172 (2006-12-13)
Frequent overexpression of epidermal growth factor receptor (EGFR) in non-small-cell lung cancer (NSCLC) makes EGFR a new therapeutic target. Two specific EGFR tyrosine kinase inhibitors, gefitinib (ZD1839, Iressa) and erlotinib (OSI-774, Tarceva), have been developed and approved by the US
An FGFR1-SPRY2 Signaling Axis Limits Basal Cell Proliferation in the Steady-State Airway Epithelium.
Gayan I Balasooriya et al.
Developmental cell, 37(1), 85-97 (2016-04-06)
The steady-state airway epithelium has a low rate of stem cell turnover but can nevertheless mount a rapid proliferative response following injury. This suggests a mechanism to restrain proliferation at steady state. One such mechanism has been identified in skeletal
Qiang Liu et al.
Nature neuroscience, 19(2), 243-252 (2016-01-12)
Recovery from organ-specific autoimmune diseases largely relies on the mobilization of endogenous repair mechanisms and local factors that control them. Natural killer (NK) cells are swiftly mobilized to organs targeted by autoimmunity and typically undergo numerical contraction when inflammation wanes.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service